AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04436796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)
Description: Use of personal pump with study CGM \& glucometer at home for 13 weeks.
Study NCT04005729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor 50 MG
Description: 30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
Study NCT02427555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barley kernel bread
Description: 3 days intervention with barley kernel bread
Study NCT02427555 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: white wheat bread
Description: 3 days intervention with white wheat bread
Study NCT00245011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
Study NCT00245011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Ifosfamide administered IV.
Study NCT00245011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
Study NCT00245011 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sm-EDTMP (low dose)
Description: Sm-EDTMP (low dose) administered after autologous stem cell collection
Study NCT00245011 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: sm-EDTMP (higher dose)
Description: Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
Study NCT02708602 — intervention group
Intervention type: GENETIC
Intervention: β2AR polymorphism
Study NCT02429921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-selenium lentils
Description: lentils grown on naturally selenium-rich soils in the Canadian Prairies
Study NCT02429921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Se lentils
Description: lentils grown on selenium-deficient soils in Idaho, USA.
Study NCT02101099 — intervention group
Intervention type: DEVICE
Intervention: Colonoscopy Force Monitor
Description: Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
Study NCT06336499 — intervention group
Intervention type: OTHER
Intervention: Multi-parametric MRI and image analysis by deep learning or machine learning algorithms
Description: Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.
Study NCT03040687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti CS6 BSIgG product (Lot PD1601105CS)
Study NCT03040687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti B7A BSIgG product (Lot PD1601132ET)
Study NCT03040687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine Immunoglobin Negative Control (Lot PD161071NC)
Study NCT03040687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7A- CS6-expressing ETEC challenge strain
Study NCT04157686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1
Description: MT10109L Dose 1 will be injected into the GL area
Study NCT04157686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 2
Description: MT10109L Dose 2 will be injected into the LCL area
Study NCT04157686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1 + Dose 2
Description: MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area
Study NCT04445155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified DECIDE Parent and Provider Intervention
Description: The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
Study NCT04445155 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified DECIDE Parent and Provider Intervention
Description: The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
Study NCT03732586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 5 fatty acid supplement
Description: Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.
Study NCT03732586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
Study NCT02385617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Study NCT02385617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Study NCT02385617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Study NCT02385617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Study NCT04565756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXN407
Description: EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
Study NCT00870506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: 5-minute video compared (intervention) to no video and no other intervention (control)
Study NCT03030885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-MIP-1095
Description: First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53
Study NCT03159845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate Oral Product
Study NCT03159845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500Mg Oral Tablet
Description: once daily from day +10 until day +30 after stem cell transplantation
Study NCT03159845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500Mg Oral Tablet
Description: once daily from day +10 until day +30 after stem cell transplantation
Study NCT03159845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 200mg tab
Description: twice daily from day +10 until day +30 after stem cell transplantation
Study NCT03159845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 200mg tab
Description: twice daily from day +10 until day +30 after stem cell transplantation
Study NCT03159845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir 400 MG
Description: twice daily from day +10 until day +30 after stem cell transplantation
Study NCT03159845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 MG
Description: twice daily from day +10 until day +30 after stem cell transplantation
Study NCT04424771 — intervention group
Intervention type: BEHAVIORAL
Intervention: Maslach Burnout Inventory (MBI)
Description: The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
Study NCT00486707 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A questionnaire will be completed.
Study NCT04909814 — intervention group
Intervention type: BIOLOGICAL
Intervention: The performance of colposcopy in vaccinated women
Description: Evaluating the performance of colpscopy in HPV vaccinated women by comparing vaccinated and unvaccinated women taking their first test within the organized screening program
Study NCT03300180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Dementia Care Program
Description: Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
Study NCT03300180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Only
Description: The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
Study NCT04315844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ewata balloon guiding
Description: The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
Study NCT01797094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (44U)
Description: 44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
Study NCT01797094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (32U)
Description: 32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
Study NCT02905643 — intervention group
Intervention type: OTHER
Intervention: Study subjects
Description: This study does not include an intervention it is only observational.
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: 2000 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
Study NCT01438814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin placebo
Description: metformin placebo tablets 500mg
Study NCT01438814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin placebo
Description: linagliptin placebo tablets 5mg
Study NCT01438814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin tablets 500mg
Study NCT01438814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablets 500 mg
Study NCT01438814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: linagliptin tablets 5mg
Study NCT01180049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temsirolimus
Description: 175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
Study NCT01180049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temsirolimus
Description: 75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
Study NCT00957424 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: telephone-based intervention
Description: 10-15 minute web-based survey on a computer
Study NCT00957424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nicotine replacement therapy
Description: One week supply
Study NCT00957424 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: informational intervention
Study NCT00957424 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: internet-based intervention
Study NCT00957424 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Description: Given out week 2, 3 and 4.
Study NCT00467558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: daily
Study NCT00467558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: daily
Study NCT01935128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 Everolimus/Reduced dose tacrolimus
Description: Immunosuppression drug intervention
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 100 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose cyclophosphamide
Description: 50 mg/kg/day on Days 2-5 of HiCy.
Study NCT00809341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET scan
Description: Performed once between Days 16-20 of cycle 3 of R-CHOP.
Study NCT04311385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT imaging
Description: CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
Study NCT01681199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin extended release tablet
Study NCT00003597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Study NCT00003597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00003597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT03937037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Description: 100ml saline irrigation after CBD stone removal with routine ERCP procedure
Study NCT03565692 — intervention group
Intervention type: BIOLOGICAL
Intervention: the lung mycobiota and microbiota profile
Description: All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~* Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~* Separation of the pellet and supernatant, stored at -20 ° C until testing~* Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~* Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~* Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~* Pseudomonas aeruginosa load measured by qPCR
Study NCT03565692 — intervention group
Intervention type: BIOLOGICAL
Intervention: the gut mycobiota and microbiota profile
Description: All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
Study NCT01961674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsinoid/placebo and rice
Description: The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
Study NCT01961674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsinoid/placebo and rice
Description: The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
Study NCT01081119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project CHOICE
Description: Voluntary after school program offered 1 day per week for 30 minutes
Study NCT03772509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CATI
Description: The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
Study NCT03892551 — intervention group
Intervention type: OTHER
Intervention: Assessment of symptoms patients presenting when admitted to ED
Description: Questionnaire with a predefined list of 35 symptoms
Study NCT03892551 — intervention group
Intervention type: OTHER
Intervention: Reason for patient presentation at ED
Description: Exploratory interview assessing reason for patient presentation at ED
Study NCT03892551 — intervention group
Intervention type: OTHER
Intervention: physicians rating of severity of illness
Description: numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)
Study NCT03892551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of vital signs
Description: Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
Study NCT03892551 — intervention group
Intervention type: OTHER
Intervention: Clinical Frailty Scale
Description: Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill
Study NCT03892551 — intervention group
Intervention type: OTHER
Intervention: Impaired mobility on presentation (IMOP)
Description: Assessment of IMOP: defined as being unable to stand unaided or walk without help
Study NCT03892551 — intervention group
Intervention type: OTHER
Intervention: Assessment of suspected diagnosis and differential diagnoses
Description: Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
Study NCT01746277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: combined group
Description: chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
Study NCT01746277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sequenced group
Description: sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
Study NCT03016949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
Study NCT03016949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: f-IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
Study NCT01264887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release
Description: Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.